BioCryst Announces Approval of Orladeyo (berotralstat) by the Brazilian Health Regulatory Agency
BioCryst Announces Approval of Orladeyo (berotralstat) by the Brazilian Health Regulatory Agency Biocryst Pharmaceuticals Inc announced that the Brazilian Health Regulatory Agency (ANVISA) has granted approval for oral, once-daily Orladeyo (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. Charlie Gayer, Chief Commercial [...]